{"entity":{"id":"essa-pharma","kind":"company","name":"ESSA Pharma","aka":[],"tldr":"ESSA Pharma developed masofaniten, an AR N-terminal-domain inhibitor whose phase 2 was stopped for futility in 2024-25.","summary":"ESSA Pharma, based in Vancouver and listed as EPIX, developed masofaniten, also known as EPI-7386, an inhibitor of the androgen receptor N-terminal domain, a target chosen because resistance to existing prostate cancer drugs often runs through that part of the receptor. Its phase 2 trial of masofaniten with enzalutamide in metastatic castration-resistant prostate cancer was terminated after a futility analysis on the PSA90 endpoint in 2024 to 2025, development was discontinued and strategic options are under review. OnCo keeps the record as an instructive failure for the AR N-terminal domain concept. Whether the target was wrong or the molecule was insufficiently potent is the question the failure leaves open. Masofaniten has its own page.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://essapharma.com"}],"tags":["failed-so-far"],"related":[],"cancers":["prostate"],"sections":["hormonal"],"technologies":[],"targets":[],"drugs":["masofaniten"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Vancouver","country":"CA","companyType":"biotech","website":"https://essapharma.com","ticker":"EPIX","investors":[],"funding":[]},"route":"/companies/essa-pharma/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"hormonal","kind":"section","name":"Hormonal Therapy","route":"/fronts/hormonal/"}],"drug":[{"id":"masofaniten","kind":"drug","name":"Masofaniten","route":"/drugs/masofaniten/"}]}}